CDKN2A companion diagnostic for bladder cancer interferon therapy
US12178865B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 13, 2022 |
| Grant date | Dec 31, 2024 |
| Priority date | — |
| Expiry date | Oct 13, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating bladder cancer comprising diagnosing bladder cancer in a human, measuring the human's level of CDKN2A expression, and then instilling into the human an agent which induces interferon expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.